Botaneco and SemBioSys Genetics Inc.

Botaneco Announces Launch of Second Generation Oleosome Product

    Calgary, Canada (ots/PRNewswire) -

    - Natural Hydresia(TM) G2 Offers Enhanced Formulation Flexibility With  a Globally Accepted Preservative System

    Botaneco, a wholly owned subsidiary of SemBioSys Genetics Inc. (TSX: SBS), focused on the development and commercialization of oleosome  technology in personal care, OTC and topical pharmaceutical markets, today  announced the launch of its second generation oleosome product, Hydresia(TM ) G2, at the In-Cosmetics 2008 exposition in Amsterdam.  Hydresia(TM) G2, a  natural emulsion base, retains all of the functional performance properties  of Botaneco's first generation Hydresia(TM) product, while offering  formulators the ability to develop products over a broader pH range (3.5- 8.5). This will allow for the development of low pH exfoliants and anti- aging products that can provide consumers with the moisturization, skin  health and aesthetic benefits that Hydresia(TM) brings to other finished  formulations.  In addition, Hydresia(TM) G2 uses a new globally accepted  preservative system that will expand the use of oleosomes in European and  other markets.

    "Botaneco is committed to developing ingredients that allow our customers to provide differentiated products that offer both performance  and aesthetic benefits to consumers," said Andrew Baum, President and CEO  of Botaneco's parent company, SemBioSys. "Hydresia(TM) G2 can be used in  moisturizers, hair and skin cleansers, lip care, color cosmetics, skin  lighteners, sun care and baby care products just like our first generation  Hydresia(TM) product.  In addition to these applications, Hydresia(TM) G2  can also be used in products where requirements for low pH have precluded the use of Hydresia(TM).  We are excited about the opportunity to expand  our product offerings in North America, as well as expanding into European  and Asian markets."

    Hydresia(TM) G2, as well as the first generation Hydresia(TM) product,  each allow cosmetic and health care formulators to develop new products  using "cold-processing" which reduces formulation and processing time by an  order of magnitude.

    Botaneco's proprietary Hydresia and Hydresia(TM) G2 products are natural emulsifiers comprised of oleosomes, natural oil carrying structures  derived from safflower seeds. Oleosomes are nature's warehouse, or storage  facility, for the emollient oils, antioxidants and natural moisture  barriers that serve to keep the skin soft, supple and young looking.  Using  a proprietary non-solvent aqueous extraction process, these oleosomes are  isolated from the seed fully intact, and when used in skin care  applications can provide lasting protection to the skin. Hydresia(TM) and  Hydresia(TM) G2 are natural, renewable replacements for hydrocarbon derived  petrolatum, mineral oil and non-ionic surfactants.

    About Botaneco

    Botaneco is the global developer and marketer of innovative oleosome- based ingredients to the personal care and OTC topical markets.  As a  technologically driven provider of high performance, proprietary oleosome  based ingredients, Botaneco is committed to developing groundbreaking  ingredients that offer multifunctional, tangible and documented benefits to  both formulators and consumers. Botaneco's manufacturing facility is  located in Calgary, Canada while its sales and marketing and research and  development laboratories are in Bensalem PA.

    More information is available and can be accessed at

    About SemBioSys (TSX:SBS)

    Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin, to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets. More information is available and can be accessed at

    This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

ots Originaltext: Botaneco and SemBioSys Genetics Inc.
Im Internet recherchierbar:

Media and Business Contact: Andrew Baum, Botaneco, Ph:
+1-403-717-8751, Fax: +1-403-250-3886, Email:,

Das könnte Sie auch interessieren: